01—Abstract
Summary
Summary of the 8-K filed October 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals, Inc. (ALNY) has announced the execution of a new Credit Agreement, establishing a $500.0 milliona revolving line of credit set to mature on September 30, 2030.
This facility, with a $150.0 millionb letter of credit sublimit, is intended to support working capital and general corporate purposes. The agreement allows for potential incremental borrowings, subject to customary conditions, and provides flexibility in interest rate options including base rate, Term SOFR, or an alternative currency rate, with margins tied to the Company's Total Leverage Ratio. The credit facility is secured by substantially all of Alnylam's and its material domestic subsidiaries' assets, with guarantees from these subsidiaries.
Key financial covenants include maintaining a Total Net Leverage Ratio of no more than 3.75:1.00 (with a potential 0.50:1.00 step-up post-Material Acquisition) and an interest coverage ratio of at least 3.00:1.00. The maturity date could be accelerated under specific conditions related to 'Springing Maturity Debt.' This new credit line provides Alnylam with significant financial flexibility and resources to fund its ongoing operations and strategic initiatives.
02—Key points
Key Highlights
- Establishment of a $500.0 million revolving credit facility maturing September 30, 2030.
- The facility includes a $150.0 million letter of credit sublimit.
- Proceeds are designated for working capital and general corporate purposes, offering financial flexibility.
- Interest rates are variable, based on base rate, Term SOFR, or alternative currency rates, plus a margin linked to the Total Leverage Ratio.
- The credit facility is secured by substantially all of the Company's and its material domestic subsidiaries' assets.
- Key financial covenants include a Total Net Leverage Ratio limit of 3.75:1.00 and an interest coverage ratio of at least 3.00:1.00.
- The maturity date has specific provisions for acceleration based on 'Springing Maturity Debt'.
03—Questions
Frequently Asked Questions
What is the primary purpose of this new credit facility?
The primary purpose of the $500.0 million revolving credit facility is to provide Alnylam Pharmaceuticals, Inc. with funding for working capital and general corporate purposes, offering enhanced financial flexibility.
What are the key financial covenants Alnylam must adhere to under this agreement?
Alnylam must maintain a Total Net Leverage Ratio less than or equal to 3.75:1.00 and a Consolidated Interest Coverage Ratio greater than or equal to 3.00:1.00, tested quarterly. The Total Net Leverage Ratio can step up by 0.50:1.00 for four quarters following a Material Acquisition under certain conditions.
How is the credit facility secured, and what is the maturity date?
The obligations under the Credit Agreement are secured by substantially all of the assets of Alnylam and its material domestic subsidiaries, with guarantees from these subsidiaries. The initial maturity date is September 30, 2030, but it can be accelerated under specific 'Springing Maturity Debt' conditions.
Does this credit facility allow for additional borrowings beyond the initial $500 million?
Yes, the Credit Agreement allows Alnylam the option to incur one or more incremental revolving commitments and/or incremental term loans, subject to certain customary conditions and requirements, though lenders are not obligated to provide these.
04—Continue